Pharma BD Deal Intelligence
Mylan bought TOBI to extend its CF/respiratory franchise and lock in orphan-drug exclusivity — instead spent years in EU courts losing the exclusivity fight, and the asset vanished into Viatris's books as an immaterial, unreported line.
Full analysis, sources & comparables →Mylan's $463M deal for Novartis's TOBI Podhaler and TOBI Solution adds an established CF franchise to its respiratory portfolio, though long-term value depends…
The transaction strengthens Mylan's CF and respiratory presence, with ~$240M payable in 2018; Novartis frames the divestment as portfolio prioritization toward…
Current TOBI Podhaler HCP/product site; FDA package insert labeler is Viatris Specialty LLC (post-2020 Mylan-Upjohn combination), confirming the franchise…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Mylan acquired worldwide commercialization rights to Novartis's cystic fibrosis franchise (TOBI Podhaler dry powder inhaler and TOBI inhalation solution) for $463M, with agreement signed July 30 and closing August 31, 2018. ~$240M payable in 2018. Strengthens Mylan's CF and respiratory portfolio with established inhaled tobramycin products.
Mylan bought TOBI to extend its CF/respiratory franchise and lock in orphan-drug exclusivity — instead spent years in EU courts losing the exclusivity fight, and the asset vanished into Viatris's books as an immaterial, unreported line.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Mylan N.V. / Novartis AG (TOBI franchise) (this deal) | 2018 | $463M | 38 |
| Mylan N.V. / Meda AB | 2016 | $9.9B | 53 |
| Mylan N.V. / Upjohn Inc. (Pfizer) | 2019 | $12.0B | 44 |
| Mylan N.V. / Renaissance Acquisition Holdings, LLC (topicals business) | 2016 | $1.0B | 40 |
| Mylan N.V. / Perrigo Company plc | 2015 | $26.0B | — |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Gilead Sciences Inc. / Pharmasset Inc. | 2011 | $11.2B | 98 |
← Browse all deals · How we score deals
More: 2018 deals · Mylan N.V. deals · Infectious Disease deals